---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-27T00:57:53.390878'
end_time: '2025-12-27T01:06:24.592074'
duration_seconds: 511.2
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: TMEM43
  gene_symbol: TMEM43
  uniprot_accession: Q9BTV4
  protein_description: 'RecName: Full=Transmembrane protein 43; AltName: Full=Protein
    LUMA;'
  gene_info: Name=TMEM43; ORFNames=UNQ2564/PRO6244;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the TMEM43 family. .
  protein_domains: TMEM43_fam. (IPR012430); TMEM43 (PF07787)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 27
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9BTV4
- **Protein Description:** RecName: Full=Transmembrane protein 43; AltName: Full=Protein LUMA;
- **Gene Information:** Name=TMEM43; ORFNames=UNQ2564/PRO6244;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the TMEM43 family. .
- **Key Domains:** TMEM43_fam. (IPR012430); TMEM43 (PF07787)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "TMEM43" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'TMEM43' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **TMEM43** (gene ID: TMEM43, UniProt: Q9BTV4) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9BTV4
- **Protein Description:** RecName: Full=Transmembrane protein 43; AltName: Full=Protein LUMA;
- **Gene Information:** Name=TMEM43; ORFNames=UNQ2564/PRO6244;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the TMEM43 family. .
- **Key Domains:** TMEM43_fam. (IPR012430); TMEM43 (PF07787)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "TMEM43" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'TMEM43' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **TMEM43** (gene ID: TMEM43, UniProt: Q9BTV4) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan
We verified the target identity (UniProt Q9BTV4; human TMEM43/LUMA), gathered recent literature (2023–2024) and authoritative reviews, extracted functional and mechanistic evidence, compiled clinical relevance and implementation, and synthesized a structured, fully cited research report.

Executive summary
TMEM43 (LUMA) encodes a four-pass integral membrane protein primarily localized to the inner nuclear membrane (INM), where it interacts with lamins and emerin and contributes to nuclear-envelope integrity and mechanotransduction. Disease-causing variants—most notably the founder p.S358L—cause arrhythmogenic right ventricular cardiomyopathy (ARVC5) with high arrhythmic risk; additional variants affect skeletal muscle (EDMD-like) and auditory function (autosomal‑dominant auditory neuropathy). Recent 2023–2024 work refined burden and penetrance estimates in ACM cohorts, expanded mechanistic insight into signaling (GSK3β/Wnt; NF‑κB–TGFβ; DDR), and introduced translational concepts including AAV-mediated WT‑TMEM43 replacement and small-molecule pathway modulation; cancer studies implicated a USP7–TMEM43–VDAC1 axis in HCC. Key statistics: ARVC prevalence ~1/1000–1/5000; SCD incidence ~0.7%/year without ICD; p.S358L onset medians ~32 years in males and ~44 in females in curated cohorts (Padua), with enrichment of TMEM43 among non‑desmosomal ACM genes (≈3.8‑fold) (mistrulli2024cardiomyopathyandsudden pages 10-11, marinas2024acomprehensiveanalysis pages 7-10).

1) Key concepts and definitions with current understanding
- Molecular identity and family/domains: TMEM43/LUMA is a conserved TMEM43-family protein with four transmembrane helices (PF07787; IPR012430), functioning as a structural/adapter component of the INM rather than as an enzyme or transporter (padillamejia2021evolutionanddiversification pages 11-13, shin2022molecularpathologyof pages 11-13).
- Subcellular localization: Predominant at the inner nuclear membrane and contiguous ER; in cardiomyocytes also detected at intercalated discs/adherens junctions; expressed in cochlear glia-like supporting cells (GLSs) (risato2024invivoapproaches pages 21-22, padillamejia2021evolutionanddiversification pages 11-13, niu2023usingzebrafishanimal pages 10-12).
- Core interactions and complexes: Interacts with emerin (EMD), lamins A/C, and SUN2, situating it within LINC-associated networks; tissue-specific interactions include connexins (Cx26/Cx30) and TASK‑1 in cochlear GLSs; studies also report VDAC1/2 relationships relevant to metabolism and cancer (risato2024invivoapproaches pages 21-22, orgil2025transmembraneprotein43 pages 2-4, zhang2024tmem43promotesthe pages 1-2).
- Primary biological role: Maintenance of nuclear-envelope integrity and mechanotransduction through lamina/emerin organization; haploinsufficiency activates DDR and drives late-onset pro‑fibrotic cardiomyopathy in mice; not a catalytic protein (shin2022molecularpathologyof pages 11-13, risato2024invivoapproaches pages 21-22).

2) Recent developments and latest research (priority to 2023–2024)
- TMEM43 as a putative channel vs structural role: A 2024 review grouped TMEM43 (“Gapjinc”) among TMEM proteins with ion-channel claims, but consensus primary role remains INM structural/adapter; electrophysiology remains tissue/context dependent and not canonical for nuclear-envelope TM proteins (kang2024transmembraneproteinswith pages 1-3).
- Mechanistic pathways in ACM: Preclinical models indicate S358L amplifies NF‑κB–TGFβ cascades and that inhibition of GSK3β rescues ARVC5 phenotypes in mice/vertebrate models, supporting Wnt/GSK3β involvement (risato2024invivoapproaches pages 21-22).
- Burden and penetrance: 2024 Padua analysis of non‑desmosomal ACM genes found TMEM43 rare P/LP variants enriched (~3.79‑fold), with curated p.S358L onset medians ~32 (male)/~44 (female) years and sex‑dependent penetrance; most other TMEM43 variants remain VUS (marinas2024acomprehensiveanalysis pages 7-10).
- Clinical risk framing: 2024 SCD review emphasizes that, unlike many ARVC genes with incomplete penetrance, TMEM43 p.S358L is fully penetrant and confers high arrhythmic risk; ARVC prevalence ~1/1000–1/5000 and SCD incidence ~0.7%/year in patients without ICD (mistrulli2024cardiomyopathyandsudden pages 10-11).
- Cancer biology: 2024 HCC study shows USP7 stabilizes TMEM43, which upregulates/activates VDAC1 to promote tumor progression; suggests an actionable USP7–TMEM43–VDAC1 axis (zhang2024tmem43promotesthe pages 1-2).
- Animal/iPSC models: Zebrafish and mouse models (including S358L knock‑in/overexpression) and human iPSC systems delineate conduction/gap-junction and nuclear-envelope defects; zebrafish screens identified GSK3β inhibition as disease-modifying (niu2023usingzebrafishanimal pages 10-12, risato2024invivoapproaches pages 21-22).

3) Current applications and real-world implementations
- Genetic testing/panels: TMEM43 is included among non‑desmosomal ACM genes with strong evidence; positive findings guide family cascade testing and lifestyle modification (avoid high-intensity exercise), with ICD consideration based on phenotype plus recognition of genotype‑specific risk (marinas2024acomprehensiveanalysis pages 7-10, mistrulli2024cardiomyopathyandsudden pages 10-11).
- Device cohorts: A 2024 tertiary-center device cohort reported TMEM43 among the more frequent positive genetic findings (≈11% of positives across a mixed arrhythmia population), illustrating real-world detection in arrhythmia/device candidates (goanta2024unexpectedgenetictwists pages 6-8).
- Imaging and risk stratification: CMR and arrhythmia history remain central to SCD risk assessment; genotype (e.g., TMEM43) adds context to risk but is not yet an independent risk predictor across all ARVC forms (mistrulli2024cardiomyopathyandsudden pages 10-11).

4) Expert opinions and analysis from authoritative sources
- Nuclear-envelope disease frameworks emphasize dual mechanisms—mechanotransduction defects and gene-expression programs—as relevant to TMEM43-linked cardiomyopathy; DDR activation and stress signaling are prominent in TMEM43 insufficiency (shin2022molecularpathologyof pages 11-13).
- Evolutionary and NE-proteome perspectives place TMEM43 among metazoan NE proteins linked to muscle/cardiac disease, interacting with lamins/emerin and LINC (padillamejia2021evolutionanddiversification pages 11-13).
- Contemporary ARVC genetics reviews and in vivo model syntheses underscore TMEM43, PLN, and DES as non-desmosomal genes with the most robust gene‑disease evidence (risato2024invivoapproaches pages 21-22, mistrulli2024cardiomyopathyandsudden pages 10-11).

5) Relevant statistics and data from recent studies
- ARVC epidemiology and outcomes: Prevalence ~1/1000–1/5000; SCD incidence ~0.7%/year in ARVC patients without ICD; lower SCD incidence among ICD recipients (mistrulli2024cardiomyopathyandsudden pages 10-11).
- TMEM43 burden/penetrance: Enrichment ratio ~3.79 for rare P/LP TMEM43 variants in select non‑desmosomal ACM cohorts; p.S358L median onset ~32 years (males) and ~44 years (females), with sex‑dependent penetrance curves; other variants mostly VUS (marinas2024acomprehensiveanalysis pages 7-10).
- Real-world testing: In a small 2018–2023 tertiary device cohort, TMEM43 comprised ~11% of positive genetic tests across heterogeneous arrhythmia/device patients (goanta2024unexpectedgenetictwists pages 6-8).

Functional annotation: mechanism, location, and pathways
- Cellular location of function: TMEM43 acts mainly at the inner nuclear membrane to scaffold lamins/emerin and connect to LINC-associated mechanotransduction, with additional roles at intercalated discs (cardiomyocyte junctional complexes) and in cochlear GLSs (gap‑junction milieu) (risato2024invivoapproaches pages 21-22, padillamejia2021evolutionanddiversification pages 11-13, niu2023usingzebrafishanimal pages 10-12).
- Interactions and complexes: Emerin (EMD) and lamin A/C interactions influence emerin distribution and NE stability; SUN2/LINC association supports nuclear–cytoskeletal force transmission; tissue-specific associations include connexins Cx26/Cx30 and TASK‑1; VDAC1/2 associations emerge in mutant/cancer contexts (risato2024invivoapproaches pages 21-22, orgil2025transmembraneprotein43 pages 2-4, zhang2024tmem43promotesthe pages 1-2).
- Mechanistic role in signaling: In ARVC5 models, S358L augments NF‑κB–TGFβ signaling and GSK3β/Wnt dysregulation; haploinsufficiency activates DDR leading to senescence and pro‑fibrotic cardiomyopathy; HCC data implicate USP7‑dependent stabilization of TMEM43 driving VDAC1 activation; auditory models suggest PI3K‑AKT and calcium signaling changes in GLS function (risato2024invivoapproaches pages 21-22, zhang2024tmem43promotesthe pages 1-2, niu2023usingzebrafishanimal pages 10-12).
- Is TMEM43 an ion channel? Evidence remains insufficient to define TMEM43 as a canonical ion channel in heart; 2024 review groups TMEM43 within TMEM channels (“Gapjinc”), but prevailing data support a structural/adapter role with potential indirect modulation of channel complexes (e.g., connexins, TASK‑1) (kang2024transmembraneproteinswith pages 1-3).

Pathogenic variants and phenotypes
- ARVC5 (p.S358L): Founder variant with high/complete penetrance and severe arrhythmic risk; increases nuclear stiffness, disrupts intercalated-disc and signaling pathways; age‑of‑onset and sex‑specific penetrance refined by 2024 analyses; founder effects documented in multiple populations (risato2024invivoapproaches pages 21-22, marinas2024acomprehensiveanalysis pages 7-10).
- EDMD-like myopathy: Missense variants such as p.E85K and p.I91V reported in EDMD phenotypes, linked to emerin mislocalization and LINC disruption in model systems (risato2024invivoapproaches pages 21-22, orgil2025transmembraneprotein43 pages 2-4).
- Auditory neuropathy spectrum disorder (ANSD): Truncating variants (e.g., Arg372Ter) associate with autosomal‑dominant ANSD; models show impaired gap‑junction communication and altered GLS signaling (orgil2025transmembraneprotein43 pages 19-21).
- Cancer associations: Overexpression or stabilization of TMEM43 promotes HCC progression via VDAC1 activation (USP7-mediated), suggesting an oncogenic module in specific contexts (zhang2024tmem43promotesthe pages 1-2).

Models, interventions, and translational directions
- Models: S358L knock‑in and transgenic mice show ARVC5 hallmarks; zebrafish overexpression/KO models recapitulate conduction and structural phenotypes; iPSC‑derived cardiomyocytes and cochlear GLSs model human cell-type phenotypes (risato2024invivoapproaches pages 21-22, niu2023usingzebrafishanimal pages 10-12, orgil2025transmembraneprotein43 pages 19-21).
- Small-molecule pathway modulation: GSK3β inhibition improves function and survival in ARVC5 models, supporting canonical Wnt involvement; ACE inhibition (enalapril) improved function and delayed mortality in preclinical ARVC5 mice (risato2024invivoapproaches pages 21-22).
- Gene therapy: Preclinical AAV‑mediated WT‑TMEM43 overexpression ameliorated S358L-driven phenotypes in mice, highlighting a replacement strategy; clinical trials have not yet been reported for TMEM43 (orgil2025transmembraneprotein43 pages 16-17, risato2024invivoapproaches pages 21-22).

Clinical implementation and guidelines
- Testing and counseling: TMEM43 is recognized among non‑desmosomal ARVC genes with robust disease association; cascade screening, exercise restriction, and ICD decisions are informed by phenotype and, for p.S358L, elevated arrhythmic risk (marinas2024acomprehensiveanalysis pages 7-10, mistrulli2024cardiomyopathyandsudden pages 10-11).
- Risk stratification: Genetic background alone is not universally an independent SCD predictor in ARVC, but TMEM43 p.S358L is an exception with high risk; CMR fibrosis/fatty infiltration and arrhythmic history remain crucial (mistrulli2024cardiomyopathyandsudden pages 10-11).

Quick-reference summary table
| Aspect | Current understanding (1–2 sentences) | 2023–2024 updates | Key sources (author/year + DOI where available) |
|---|---|---|---|
| Identity / domains | TMEM43 (LUMA) is a conserved ~43 kDa integral membrane protein belonging to the TMEM43 family with four transmembrane helices; annotated domains include TMEM43_fam (IPR012430) / PF07787. | Structural models and proteomic annotation reinforce a 4-TM topology with oligomerization interfaces and predicted post‑translational modification sites; some analyses propose an intramembrane pore-like region (TM3/Loop2). | Padilla‑Mejia 2021 https://doi.org/10.1080/19491034.2021.1874135 (padillamejia2021evolutionanddiversification pages 11-13), Kang 2024 https://doi.org/10.1038/s12276-024-01206-1 (kang2024transmembraneproteinswith pages 1-3) |
| Subcellular localization | Predominantly localized to the inner nuclear membrane (INM) and endoplasmic reticulum; reported additional localization to cardiac intercalated discs and adherens junctions in cardiomyocytes and to cochlear glial support cells. | Recent proteomic and imaging studies (animal and cell models) confirm INM targeting via lamin interactions and document functional presence at intercalated discs and cochlear GLSs in 2023–2024 models. | Padilla‑Mejia 2021 (padillamejia2021evolutionanddiversification pages 11-13), Risato 2024 https://doi.org/10.3390/cells13151264 (risato2024invivoapproaches pages 21-22), Niu 2023 https://doi.org/10.3390/ijms24044106 (niu2023usingzebrafishanimal pages 10-12) |
| Interacting partners | Biochemical and cell biology studies report interactions with emerin (EMD), lamin A/C, SUN proteins (LINC complex components); additional reported partners include VDAC1/2, connexins (Cx26/Cx30) and TASK‑1 in tissue-specific contexts. | 2023–2024 IP/proximity studies and cancer work show altered VDAC binding for S358L and a TMEM43–VDAC1 regulatory axis (USP7-mediated) in HCC; cochlear models show connexin complex perturbation. | Zhang 2024 https://doi.org/10.21037/tgh-23-108 (zhang2024tmem43promotesthe pages 1-2), Orgil 2025 (TMEM43 review extract) (orgil2025transmembraneprotein43 pages 2-4), Kang 2024 (kang2024transmembraneproteinswith pages 1-3) |
| Primary molecular / biological functions | Functions primarily as an INM structural/adapter protein that helps maintain nuclear envelope integrity, organize emerin/lamina interactions, and contribute to mechanotransduction; not classified as an enzyme or canonical transporter. | Functional studies (haploinsufficiency, KO) implicate TMEM43 in maintaining NE stability and preventing activation of DNA damage responses; in cochlea, TMEM43 influences glial K+ handling/gap‑junction communication. | Shin & Worman 2022 https://doi.org/10.1146/annurev-pathol-042220-034240 (shin2022molecularpathologyof pages 11-13), Risato 2024 (risato2024invivoapproaches pages 21-22), Niu 2023 (niu2023usingzebrafishanimal pages 10-12) |
| Pathways implicated | Linked mechanistically to LINC/mechanotransduction pathways, and reported to influence Wnt/GSK3β, NF‑κB–TGFβ signaling, DDR (DNA damage response), lipid metabolism and ferroptosis-related processes. | 2023–2024 data: S358L models amplify NF‑κB–TGFβ signaling and Wnt/GSK3β modulation (GSK3β inhibitors rescue phenotypes in models); cancer studies implicate USP7–TMEM43–VDAC1 axis (VDAC regulation) in tumor progression. | Zheng et al. (cited in Risato) / Padrón‑Barthe 2019 (risato2024invivoapproaches pages 21-22), Zhang 2024 (zhang2024tmem43promotesthe pages 1-2), Kang 2024 (kang2024transmembraneproteinswith pages 1-3) |
| Pathogenic variants & penetrance | The founder missense p.S358L (c.1073C>T) causes ARVC5 with marked arrhythmic risk; other missense (e.g., p.E85K, p.I91V) reported in EDMD-like myopathies; truncating/nonsense variants linked to auditory neuropathy phenotypes. | Cohort re-analyses (2023–2024) refine age-of-onset/penetrance estimates for p.S358L (median onset ~32 males/44 females) and confirm founder effects; numerous other rare variants remain VUS or require functional validation. | Marinas 2024 https://doi.org/10.3390/ijms25116267 (marinas2024acomprehensiveanalysis pages 7-10), Risato 2024 (risato2024invivoapproaches pages 21-22), Mistrulli 2024 https://doi.org/10.3390/biomedicines12071602 (mistrulli2024cardiomyopathyandsudden pages 10-11) |
| Disease areas (cardiac, neuromuscular, auditory, cancer) | Clinically linked to arrhythmogenic cardiomyopathy/ARVC (notably ARVC5), Emery–Dreifuss–like myopathies, autosomal‑dominant auditory neuropathy (ANSD) and reported associations with cancers (HCC, pancreatic). | 2023–2024 model and clinical studies strengthened cardiac and auditory mechanistic links; 2024 reports implicate TMEM43 in HCC via VDAC1/USP7 signaling and in tumor cell survival. | Marinas 2024 (marinas2024acomprehensiveanalysis pages 7-10), Zhang 2024 (zhang2024tmem43promotesthe pages 1-2), Niu 2023 (niu2023usingzebrafishanimal pages 10-12) |
| Models & mechanistic insights | Experimental systems include S358L knock‑in and overexpression mouse models, zebrafish transgenic/KO models, TMEM43 KO/haploinsufficient mice, and human iPSC-derived cardiomyocytes and cochlear GLSs. | 2023 knock‑in mice show cardiac, intestinal and metabolic effects; zebrafish and iPSC GLS models (2023–2024) reveal conduction/gap-junction and ionic homeostasis defects; AAV-mediated WT‑TMEM43 rescue shown preclinically. | Orgil/Orgil review extracts (orgil2025transmembraneprotein43 pages 1-2), Niu 2023 (niu2023usingzebrafishanimal pages 10-12), Risato 2024 (risato2024invivoapproaches pages 21-22) |
| Therapeutic concepts / clinical implementation | No approved TMEM43‑targeted therapies yet; preclinical strategies include AAV-mediated WT‑TMEM43 gene delivery and pathway-targeting small molecules (e.g., GSK3β inhibitors) that modulate downstream signaling. | Preclinical AAV‑WT rescue (mouse) and small-molecule rescue in zebrafish/other ACM models reported (proof‑of‑concept); clinical guidelines increasingly recognize TMEM43 among non‑desmosomal genes warranting surveillance. | Risato 2024 (risato2024invivoapproaches pages 21-22), Mistrulli 2024 (mistrulli2024cardiomyopathyandsudden pages 10-11), Orgil review extracts (orgil2025transmembraneprotein43 pages 2-4) |
| Cohort / burden analyses & guideline placement | TMEM43 variants are rare overall but p.S358L is a population/founder variant with strong disease association; analyses show enrichment of TMEM43 among non‑desmosomal ACM genes in some cohorts. | 2024 Padua cohort and other reappraisals report ~3.8‑fold enrichment for TMEM43 rare P/LP variants in selected ACM cohorts and provide age/penetrance estimates; 2023 ESC/guideline discussions place TMEM43 among a small set of non‑desmosomal genes with substantive evidence. | Marinas 2024 https://doi.org/10.3390/ijms25116267 (marinas2024acomprehensiveanalysis pages 7-10), Mistrulli 2024 (mistrulli2024cardiomyopathyandsudden pages 10-11) |


*Table: Concise table summarizing TMEM43 identity, localization, interactions, function, disease links, models, therapeutic concepts, and 2023–2024 updates with primary sources for quick reference.*

URLs (representative recent sources)
- Kang 2024, Experimental & Molecular Medicine: https://doi.org/10.1038/s12276-024-01206-1 (TMEM43/“Gapjinc”) (kang2024transmembraneproteinswith pages 1-3)
- Zhang 2024, Translational Gastroenterology and Hepatology: https://doi.org/10.21037/tgh-23-108 (USP7–TMEM43–VDAC1 in HCC) (zhang2024tmem43promotesthe pages 1-2)
- Marinas 2024, Int J Mol Sci: https://doi.org/10.3390/ijms25116267 (Padua cohort, non‑desmosomal ACM burden; TMEM43 penetrance) (marinas2024acomprehensiveanalysis pages 7-10)
- Mistrulli 2024, Biomedicines: https://doi.org/10.3390/biomedicines12071602 (ARVC epidemiology; TMEM43 p.S358L risk) (mistrulli2024cardiomyopathyandsudden pages 10-11)
- Risato 2024, Cells: https://doi.org/10.3390/cells13151264 (in vivo ACM models; TMEM43 citations) (risato2024invivoapproaches pages 21-22)
- Niu 2023, Int J Mol Sci: https://doi.org/10.3390/ijms24044106 (zebrafish ACM models; GSK3β inhibitor rescue) (niu2023usingzebrafishanimal pages 10-12)
- Shin & Worman 2022, Annu Rev Pathol: https://doi.org/10.1146/annurev-pathol-042220-034240 (NE disease mechanisms) (shin2022molecularpathologyof pages 11-13)
- Padilla‑Mejia 2021, Nucleus: https://doi.org/10.1080/19491034.2021.1874135 (evolution/NE disease mapping; TMEM43 interactions) (padillamejia2021evolutionanddiversification pages 11-13)
- Goanta 2024, J Clin Med: https://doi.org/10.3390/jcm13133801 (device cohort; TMEM43 frequency among positives) (goanta2024unexpectedgenetictwists pages 6-8)

Limitations and open questions
- Ion-channel claims for TMEM43 remain debated and tissue‑specific; definitive electrophysiology in cardiomyocytes is lacking compared to strong INM structural evidence (kang2024transmembraneproteinswith pages 1-3).
- Many TMEM43 variants remain VUS; functional validation is needed to clarify pathogenicity and mechanism (marinas2024acomprehensiveanalysis pages 7-10).
- Translational therapies (AAV WT‑TMEM43, GSK3β inhibitors) are preclinical; no human trials yet specifically targeting TMEM43 (risato2024invivoapproaches pages 21-22).

Verification of target identity and organism
All data herein refer to human TMEM43 (UniProt Q9BTV4; LUMA), a TMEM43-family protein localized to the INM/ER and junctional structures, consistent with UniProt domains and family membership. No conflicting gene-symbol usage was used (padillamejia2021evolutionanddiversification pages 11-13, shin2022molecularpathologyof pages 11-13, risato2024invivoapproaches pages 21-22).

References

1. (mistrulli2024cardiomyopathyandsudden pages 10-11): Raffaella Mistrulli, Armando Ferrera, Luigi Salerno, Federico Vannini, Leonardo Guida, Sara Corradetti, Lucio Addeo, Stefano Valcher, Giuseppe Di Gioia, Francesco Raffaele Spera, Giuliano Tocci, and Emanuele Barbato. Cardiomyopathy and sudden cardiac death: bridging clinical practice with cutting-edge research. Biomedicines, 12:1602, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071602, doi:10.3390/biomedicines12071602. This article has 11 citations and is from a poor quality or predatory journal.

2. (marinas2024acomprehensiveanalysis pages 7-10): Maria Bueno Marinas, Marco Cason, Riccardo Bariani, Rudy Celeghin, Monica De Gaspari, Serena Pinci, Alberto Cipriani, Ilaria Rigato, Alessandro Zorzi, Stefania Rizzo, Gaetano Thiene, Martina Perazzolo Marra, Domenico Corrado, Cristina Basso, Barbara Bauce, and Kalliopi Pilichou. A comprehensive analysis of non-desmosomal rare genetic variants in arrhythmogenic cardiomyopathy: integrating in padua cohort literature-derived data. International Journal of Molecular Sciences, 25:6267, Jun 2024. URL: https://doi.org/10.3390/ijms25116267, doi:10.3390/ijms25116267. This article has 7 citations and is from a poor quality or predatory journal.

3. (padillamejia2021evolutionanddiversification pages 11-13): Norma E. Padilla-Mejia, Alexandr A. Makarov, Lael D. Barlow, Erin R. Butterfield, and Mark C. Field. Evolution and diversification of the nuclear envelope. Nucleus, 12:21-41, Jan 2021. URL: https://doi.org/10.1080/19491034.2021.1874135, doi:10.1080/19491034.2021.1874135. This article has 11 citations and is from a peer-reviewed journal.

4. (shin2022molecularpathologyof pages 11-13): Ji-Yeon Shin and Howard J. Worman. Molecular pathology of laminopathies. Annual Review of Pathology: Mechanisms of Disease, 17:159-180, Jan 2022. URL: https://doi.org/10.1146/annurev-pathol-042220-034240, doi:10.1146/annurev-pathol-042220-034240. This article has 121 citations and is from a domain leading peer-reviewed journal.

5. (risato2024invivoapproaches pages 21-22): Giovanni Risato, Raquel Brañas Casas, Marco Cason, Maria Bueno Marinas, Serena Pinci, Monica De Gaspari, Silvia Visentin, Stefania Rizzo, Gaetano Thiene, Cristina Basso, Kalliopi Pilichou, Natascia Tiso, and Rudy Celeghin. In vivo approaches to understand arrhythmogenic cardiomyopathy: perspectives on animal models. Cells, Jul 2024. URL: https://doi.org/10.3390/cells13151264, doi:10.3390/cells13151264. This article has 2 citations and is from a poor quality or predatory journal.

6. (niu2023usingzebrafishanimal pages 10-12): Yujuan Niu, Yuanchao Sun, Yuting Liu, Ke Du, Xiaolei Xu, and Yonghe Ding. Using zebrafish animal model to study the genetic underpinning and mechanism of arrhythmogenic cardiomyopathy. International Journal of Molecular Sciences, 24:4106, Feb 2023. URL: https://doi.org/10.3390/ijms24044106, doi:10.3390/ijms24044106. This article has 5 citations and is from a poor quality or predatory journal.

7. (orgil2025transmembraneprotein43 pages 2-4): Buyan-Ochir Orgil, Mekaea S. Spaulding, Harrison P. Smith, Zainab Baba, Neely R. Alberson, Enkhzul Batsaikhan, Jeffrey A Towbin, and E. Purevjav. Transmembrane protein 43: molecular and pathogenetic implications in arrhythmogenic cardiomyopathy and various other diseases. International Journal of Molecular Sciences, Jul 2025. URL: https://doi.org/10.3390/ijms26146856, doi:10.3390/ijms26146856. This article has 2 citations and is from a poor quality or predatory journal.

8. (zhang2024tmem43promotesthe pages 1-2): Nannan Zhang, Feiran Wang, Xiaobing Yang, Quhui Wang, Renan Chang, Lirong Zhu, Mark A. Feitelson, and Zhong Chen. Tmem43 promotes the development of hepatocellular carcinoma by activating vdac1 through usp7 deubiquitination. Translational Gastroenterology and Hepatology, 9:9-9, Jan 2024. URL: https://doi.org/10.21037/tgh-23-108, doi:10.21037/tgh-23-108. This article has 8 citations and is from a peer-reviewed journal.

9. (kang2024transmembraneproteinswith pages 1-3): Hyunji Kang and C. Justin Lee. Transmembrane proteins with unknown function (tmems) as ion channels: electrophysiological properties, structure, and pathophysiological roles. Experimental & Molecular Medicine, 56:850-860, Apr 2024. URL: https://doi.org/10.1038/s12276-024-01206-1, doi:10.1038/s12276-024-01206-1. This article has 29 citations and is from a peer-reviewed journal.

10. (goanta2024unexpectedgenetictwists pages 6-8): Emilia-Violeta Goanta, Cristina Vacarescu, Georgica Tartea, Adrian Ungureanu, Sebastian Militaru, Alexandra Muraretu, Adelina-Andreea Faur-Grigori, Lucian Petrescu, Radu Vătăsescu, and Dragos Cozma. Unexpected genetic twists in patients with cardiac devices. Journal of Clinical Medicine, 13:3801, Jun 2024. URL: https://doi.org/10.3390/jcm13133801, doi:10.3390/jcm13133801. This article has 1 citations and is from a poor quality or predatory journal.

11. (orgil2025transmembraneprotein43 pages 19-21): Buyan-Ochir Orgil, Mekaea S. Spaulding, Harrison P. Smith, Zainab Baba, Neely R. Alberson, Enkhzul Batsaikhan, Jeffrey A Towbin, and E. Purevjav. Transmembrane protein 43: molecular and pathogenetic implications in arrhythmogenic cardiomyopathy and various other diseases. International Journal of Molecular Sciences, Jul 2025. URL: https://doi.org/10.3390/ijms26146856, doi:10.3390/ijms26146856. This article has 2 citations and is from a poor quality or predatory journal.

12. (orgil2025transmembraneprotein43 pages 16-17): Buyan-Ochir Orgil, Mekaea S. Spaulding, Harrison P. Smith, Zainab Baba, Neely R. Alberson, Enkhzul Batsaikhan, Jeffrey A Towbin, and E. Purevjav. Transmembrane protein 43: molecular and pathogenetic implications in arrhythmogenic cardiomyopathy and various other diseases. International Journal of Molecular Sciences, Jul 2025. URL: https://doi.org/10.3390/ijms26146856, doi:10.3390/ijms26146856. This article has 2 citations and is from a poor quality or predatory journal.

13. (orgil2025transmembraneprotein43 pages 1-2): Buyan-Ochir Orgil, Mekaea S. Spaulding, Harrison P. Smith, Zainab Baba, Neely R. Alberson, Enkhzul Batsaikhan, Jeffrey A Towbin, and E. Purevjav. Transmembrane protein 43: molecular and pathogenetic implications in arrhythmogenic cardiomyopathy and various other diseases. International Journal of Molecular Sciences, Jul 2025. URL: https://doi.org/10.3390/ijms26146856, doi:10.3390/ijms26146856. This article has 2 citations and is from a poor quality or predatory journal.

## Citations

1. kang2024transmembraneproteinswith pages 1-3
2. risato2024invivoapproaches pages 21-22
3. marinas2024acomprehensiveanalysis pages 7-10
4. mistrulli2024cardiomyopathyandsudden pages 10-11
5. goanta2024unexpectedgenetictwists pages 6-8
6. shin2022molecularpathologyof pages 11-13
7. padillamejia2021evolutionanddiversification pages 11-13
8. niu2023usingzebrafishanimal pages 10-12
9. https://doi.org/10.1080/19491034.2021.1874135
10. https://doi.org/10.1038/s12276-024-01206-1
11. https://doi.org/10.3390/cells13151264
12. https://doi.org/10.3390/ijms24044106
13. https://doi.org/10.21037/tgh-23-108
14. https://doi.org/10.1146/annurev-pathol-042220-034240
15. https://doi.org/10.3390/ijms25116267
16. https://doi.org/10.3390/biomedicines12071602
17. https://doi.org/10.3390/jcm13133801
18. https://doi.org/10.3390/biomedicines12071602,
19. https://doi.org/10.3390/ijms25116267,
20. https://doi.org/10.1080/19491034.2021.1874135,
21. https://doi.org/10.1146/annurev-pathol-042220-034240,
22. https://doi.org/10.3390/cells13151264,
23. https://doi.org/10.3390/ijms24044106,
24. https://doi.org/10.3390/ijms26146856,
25. https://doi.org/10.21037/tgh-23-108,
26. https://doi.org/10.1038/s12276-024-01206-1,
27. https://doi.org/10.3390/jcm13133801,